

Asparaginase

NOT RECOMMENDED AS AN
ESSENTIAL MEDICINE

Section: 8. Immunomodulators and antineoplastics > 8.2. Antineoplastics and supportive medicines > 8.2.1. Cytotoxic medicines

		EMLc	ATC codes: L01XX02
Indication	Unspecified malignant neoplasms of ill-defined or unspecified sites	ICD11 code: 2D9Z	
Medicine type	Biological agent		
List type	Complementary (EML) (EMLc)		
Formulations	Powder for injection: 10 000 IU in vial.		
EML status history	First added in 1993 (TRS 850) Changed in 2007 (TRS 950) Removed in 2015 (TRS 994)		
Sex	All		
Age	Also recommended for children		
Therapeutic alternatives	The recommendation is for this specific medicine		
Patent information	Patents have expired in most jurisdictions Read more about patents .		
Tags	Cancer Biological		
Wikipedia	Asparaginase		
DrugBank	Asparaginase		

Summary of evidence and Expert Committee recommendations

As part of the comprehensive review of cancer medicines undertaken by the Expert Committee in 2015, listing of asparaginase was reviewed and specific indications for its use were recommended. Refer to the 2015 recommendation(s) for asparaginase for more information.

